Barclays Lowers Price Target on Certara to $16 From $18, Maintains Equalweight Rating
Certara Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Certara Analyst Maintains Hold Rating Amid Mixed Financial Performance and Strategic Developments
Certara (CERT) Gets a Hold From Barclays
Certara (CERT) Gets a Hold From JMP Securities
R1 RCM, Health Catalyst Downgraded as KeyBanc Reviews Health-tech Space
Certara Analyst Ratings
Barclays Remains a Hold on Certara (CERT)
Certara Analyst Ratings
Certara Analyst Ratings
Barclays Issues a Hold Rating on Certara (CERT)
Leerink Partners Initiates Coverage On Certara With Market Perform Rating, Announces Price Target of $19
Certara Analyst Ratings
Certara Analyst Ratings
UBS Initiates Coverage On Certara With Neutral Rating, Announces Price Target of $17
Certara Analyst Ratings
Certara Analyst Ratings
BofA Securities Adjusts Price Target on Certara to $20 From $24, Maintains Buy Rating
The Latest Analyst Ratings for Certara
No Data